Misiag P, Molik K, Kisielewska M, Typek P, Skowron I, Karwowska A
Int J Mol Sci. 2024; 25(21).
PMID: 39519055
PMC: 11546312.
DOI: 10.3390/ijms252111502.
Ohguro H, Watanabe M, Sato T, Nishikiori N, Umetsu A, Higashide M
Cells. 2024; 13(18.
PMID: 39329734
PMC: 11430518.
DOI: 10.3390/cells13181549.
du Plessis L, Gouws C, Nieto D
Front Cell Dev Biol. 2024; 12:1391259.
PMID: 38835508
PMC: 11148284.
DOI: 10.3389/fcell.2024.1391259.
Ortiz Jordan L, Fernandez Vega V, Shumate J, Peles A, Zeiger J, Scampavia L
SLAS Discov. 2024; 29(3):100141.
PMID: 38218316
PMC: 11542555.
DOI: 10.1016/j.slasd.2024.01.002.
Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M
Mol Cancer. 2023; 22(1):189.
PMID: 38017433
PMC: 10683363.
DOI: 10.1186/s12943-023-01873-0.
Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors.
Zhou S, Lu J, Liu S, Shao J, Liu Z, Li J
Front Cell Dev Biol. 2023; 11:1166916.
PMID: 37152280
PMC: 10154581.
DOI: 10.3389/fcell.2023.1166916.
3D Spheroid Configurations Are Possible Indictors for Evaluating the Pathophysiology of Melanoma Cell Lines.
Ohguro H, Watanabe M, Sato T, Hikage F, Furuhashi M, Okura M
Cells. 2023; 12(5).
PMID: 36899895
PMC: 10000690.
DOI: 10.3390/cells12050759.
Growth and adaptation mechanisms of tumour spheroids with time-dependent oxygen availability.
Murphy R, Gunasingh G, Haass N, Simpson M
PLoS Comput Biol. 2023; 19(1):e1010833.
PMID: 36634128
PMC: 9876349.
DOI: 10.1371/journal.pcbi.1010833.
In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis.
Wussmann M, Groeber-Becker F, Riedl S, Alihodzic D, Padaric D, Gerlitz L
Biomedicines. 2022; 10(11).
PMID: 36428530
PMC: 9687695.
DOI: 10.3390/biomedicines10112961.
A preclinical model of cutaneous melanoma based on reconstructed human epidermis.
Leikeim A, Wussmann M, Schmidt F, Neto N, Benz F, Tiltmann K
Sci Rep. 2022; 12(1):16269.
PMID: 36175453
PMC: 9522649.
DOI: 10.1038/s41598-022-19307-0.
From simplicity to complexity in current melanoma models.
Michielon E, de Gruijl T, Gibbs S
Exp Dermatol. 2022; 31(12):1818-1836.
PMID: 36103206
PMC: 10092692.
DOI: 10.1111/exd.14675.
A stochastic mathematical model of 4D tumour spheroids with real-time fluorescent cell cycle labelling.
Klowss J, Browning A, Murphy R, Carr E, Plank M, Gunasingh G
J R Soc Interface. 2022; 19(189):20210903.
PMID: 35382573
PMC: 8984298.
DOI: 10.1098/rsif.2021.0903.
The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.
Matias M, Pinho J, Penetra M, Campos G, Reis C, Gaspar M
Cells. 2021; 10(11).
PMID: 34831311
PMC: 8621991.
DOI: 10.3390/cells10113088.
Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?.
Varrone F, Mandrich L, Caputo E
Cancers (Basel). 2021; 13(22).
PMID: 34830940
PMC: 8616100.
DOI: 10.3390/cancers13225788.
Fluorescence-Based Quantitative and Spatial Analysis of Tumour Spheroids: A Proposed Tool to Predict Patient-Specific Therapy Response.
Spoerri L, Gunasingh G, Haass N
Front Digit Health. 2021; 3:668390.
PMID: 34713141
PMC: 8521823.
DOI: 10.3389/fdgth.2021.668390.
Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape.
Battaglia L, Scomparin A, Dianzani C, Milla P, Muntoni E, Arpicco S
Pharmaceutics. 2021; 13(10).
PMID: 34683910
PMC: 8540596.
DOI: 10.3390/pharmaceutics13101617.
Multitargeting Effects of Calebin A on Malignancy of CRC Cells in Multicellular Tumor Microenvironment.
Buhrmann C, Kunnumakkara A, Kumar A, Samec M, Kubatka P, Aggarwal B
Front Oncol. 2021; 11:650603.
PMID: 34660256
PMC: 8511772.
DOI: 10.3389/fonc.2021.650603.
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression.
Saltari A, Dzung A, Quadri M, Tiso N, Facchinello N, Hernandez-Barranco A
Cancer Res. 2021; 81(23):6044-6057.
PMID: 34645608
PMC: 9397645.
DOI: 10.1158/0008-5472.CAN-21-0117.
Estimating parameters of a stochastic cell invasion model with fluorescent cell cycle labelling using approximate Bayesian computation.
Carr M, Simpson M, Drovandi C
J R Soc Interface. 2021; 18(182):20210362.
PMID: 34547212
PMC: 8455172.
DOI: 10.1098/rsif.2021.0362.
A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.
Uranowska K, Samadaei M, Kalic T, Pinter M, Breiteneder H, Hafner C
Int J Oncol. 2021; 59(3).
PMID: 34318902
PMC: 8357264.
DOI: 10.3892/ijo.2021.5250.